Unlocked, right on the stroke of 5!

Data looks good - TI delivered via the GEN 2 device shows the same bioavailability as the Medtone device.

Medtone:

20-25%

http://www.unboundmedicine.com/evidence/ub/citation/19476477/Pharmacokinetics_and_linear_exposure_of_AFRESA_compared_with_the_subcutaneous_injection_of_regular_human_insulin_

Gen 2:

24%

http://app.core-apps.com/tristar_ada13/abstract/9b942b88cb23351f1c62fdf8084f9f61

Which to me means that the device comparison should be good?

Only concern were hypoglycemic events:

The most frequent adverse event was mild asymptomatic hypoglycemia reported for 85% of subjects after TI dosing and 12.5% following sc insulin which was classified as related to study procedure (ie inability of glucose infusion to respond at a rate to maintain euglycemia post-dosing).

Liane / Anyone:

Can you weigh in on the bioavailability / difference in hypoglycemic events seen?